IL315798A - Alpha 1A-adrenergic receptor agonists and methods of use - Google Patents
Alpha 1A-adrenergic receptor agonists and methods of useInfo
- Publication number
- IL315798A IL315798A IL315798A IL31579824A IL315798A IL 315798 A IL315798 A IL 315798A IL 315798 A IL315798 A IL 315798A IL 31579824 A IL31579824 A IL 31579824A IL 315798 A IL315798 A IL 315798A
- Authority
- IL
- Israel
- Prior art keywords
- alpha
- methods
- receptor agonists
- adrenergic receptor
- adrenergic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323421P | 2022-03-24 | 2022-03-24 | |
| PCT/US2023/015914 WO2023183394A1 (en) | 2022-03-24 | 2023-03-22 | Alpha 1a-adrenergic receptor agonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315798A true IL315798A (en) | 2024-11-01 |
Family
ID=88101941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315798A IL315798A (en) | 2022-03-24 | 2023-03-22 | Alpha 1A-adrenergic receptor agonists and methods of use |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250188060A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4499070A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025512777A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240165433A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119013020A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023240170A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245920A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315798A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011674A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023183394A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2337909C2 (ru) * | 2002-02-01 | 2008-11-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора |
| CA2637312A1 (en) * | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| DK3421471T3 (da) * | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
-
2023
- 2023-03-22 CN CN202380029402.1A patent/CN119013020A/zh active Pending
- 2023-03-22 JP JP2024556112A patent/JP2025512777A/ja active Pending
- 2023-03-22 KR KR1020247035218A patent/KR20240165433A/ko active Pending
- 2023-03-22 EP EP23775602.8A patent/EP4499070A1/en active Pending
- 2023-03-22 CA CA3245920A patent/CA3245920A1/en active Pending
- 2023-03-22 US US18/847,147 patent/US20250188060A1/en active Pending
- 2023-03-22 MX MX2024011674A patent/MX2024011674A/es unknown
- 2023-03-22 AU AU2023240170A patent/AU2023240170A1/en active Pending
- 2023-03-22 IL IL315798A patent/IL315798A/en unknown
- 2023-03-22 WO PCT/US2023/015914 patent/WO2023183394A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024011674A (es) | 2024-09-27 |
| US20250188060A1 (en) | 2025-06-12 |
| AU2023240170A1 (en) | 2024-10-31 |
| EP4499070A1 (en) | 2025-02-05 |
| CA3245920A1 (en) | 2023-09-28 |
| JP2025512777A (ja) | 2025-04-22 |
| WO2023183394A1 (en) | 2023-09-28 |
| KR20240165433A (ko) | 2024-11-22 |
| CN119013020A (zh) | 2024-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310221A (en) | IL12 receptor agonists and methods of using them | |
| IL310378A (en) | Serotonin receptor agonists that cause hallucinations and that do not cause hallucinations and methods for their preparation and use | |
| GB202019709D0 (en) | Anti-Coronavirus antibodies and methods of use | |
| IL277337A (en) | Antibodies against alpha signal modulatory protein and methods of use | |
| IL305944A (en) | Agonistic anti-IL-2R antibodies and methods of use | |
| IL312348A (en) | HIF-2ALPHA inhibitors and methods of using it | |
| IL304680A (en) | Urolithin history and methods of using them | |
| IL299245A (en) | LAIR-1 binding agents and methods of using them | |
| IL316619A (en) | PI3Kα inhibitors and methods of using them | |
| IL314320A (en) | Compounds and methods of use | |
| IL316368A (en) | Anti-TL1A antibodies and methods of using them | |
| SG11202109589VA (en) | T cell receptors and methods of use thereof | |
| SG11202109595TA (en) | T cell receptors and methods of use thereof | |
| SG11202109588RA (en) | T cell receptors and methods of use thereof | |
| SG11202109593SA (en) | T cell receptors and methods of use thereof | |
| SG11202109590VA (en) | T cell receptors and methods of use thereof | |
| IL315845A (en) | Anti-dectin-1 antibodies and methods of using them | |
| CA3245328A1 (en) | Anti-alpha folate receptor antibodies and methods of use | |
| IL318393A (en) | Azaquinazoline compounds and methods of use | |
| SG11202109594PA (en) | T cell receptors and methods of use thereof | |
| IL299104A (en) | Intracellular administration of a CEBP antagonist and methods of use | |
| IL315798A (en) | Alpha 1A-adrenergic receptor agonists and methods of use | |
| EP4110322A4 (en) | SELECTIVE COVALENT ANDROGEN RECEPTOR ANTAGONISTS (SARCAS) AND METHODS OF USE THEREOF | |
| IL319978A (en) | NEK7 joints and methods of using them | |
| IL317690A (en) | Anti-GPNMB antibodies and methods of using them |